Approximately 80 participants will be assigned across two substudies, with approximately 40 evaluable participants for study intervention in each corresponding substudy.
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.